Form 8-K - Current report:
SEC Accession No. 0001641172-25-000300
Filing Date
2025-03-24
Accepted
2025-03-24 16:30:30
Documents
14
Period of Report
2025-03-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 41452
2 ex10-1.htm EX-10.1 65055
  Complete submission text file 0001641172-25-000300.txt   292658

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE erna-20250320.xsd EX-101.SCH 3015
4 XBRL LABEL FILE erna-20250320_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE erna-20250320_pre.xml EX-101.PRE 22359
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3698
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 25764546
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)